JNJ
188.98
-0.04%↓
ABT
123.58
-0.84%↓
TMO
568.01
+2.1%↑
ISRG
534.39
+0.84%↑
DHR
215.62
+0.34%↑
JNJ
188.98
-0.04%↓
ABT
123.58
-0.84%↓
TMO
568.01
+2.1%↑
ISRG
534.39
+0.84%↑
DHR
215.62
+0.34%↑
JNJ
188.98
-0.04%↓
ABT
123.58
-0.84%↓
TMO
568.01
+2.1%↑
ISRG
534.39
+0.84%↑
DHR
215.62
+0.34%↑
JNJ
188.98
-0.04%↓
ABT
123.58
-0.84%↓
TMO
568.01
+2.1%↑
ISRG
534.39
+0.84%↑
DHR
215.62
+0.34%↑
JNJ
188.98
-0.04%↓
ABT
123.58
-0.84%↓
TMO
568.01
+2.1%↑
ISRG
534.39
+0.84%↑
DHR
215.62
+0.34%↑
24h
Current
Min
16.39
Max
16.74
Income | 9.5M -43M |
|---|---|
Sales | 1K 8K |
EPS | -2.89 |
Profit margin | -533,550 |
Employees | 300 |
EBITDA | 11M -43M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -15.97% downside |
Market Cap | 128M 331M |
|---|---|
Previous open | 15.78 |
Previous close | 16.39 |
By Trading Central
Confidence
Strong Bearish Evidence
0.4217 / 0.4691 Support & Resistance
Past performance is not a reliable indicator of future results.
2 Nov 2025, 22:13 UTC
Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update
DJ
Read
2 Nov 2025, 21:23 UTC
Westpac Raises Dividend Despite 1% Slip in Annual Profit
DJ
Read
2 Nov 2025, 23:43 UTC
Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk
DJ
Read
2 Nov 2025, 23:34 UTC
Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk
DJ
Read
2 Nov 2025, 21:00 UTC
Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU
DJ
Read
2 Nov 2025, 21:00 UTC
Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU
DJ
Read
2 Nov 2025, 21:00 UTC
Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU
DJ
Read
2 Nov 2025, 20:55 UTC
Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU
DJ
Read
2 Nov 2025, 20:55 UTC
Westpac FY Institutional Lending Up 17% on Year>WBC.AU
DJ
Read
2 Nov 2025, 20:55 UTC
Westpac FY Business Lending Up 15% on Year>WBC.AU
DJ
Read
2 Nov 2025, 20:46 UTC
Westpac Expects Completion in 2H of FY 2026>WBC.AU
DJ
Read
2 Nov 2025, 20:46 UTC
Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU
DJ
Read
2 Nov 2025, 20:45 UTC
Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU
DJ
Read
2 Nov 2025, 20:44 UTC
Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU
DJ
Read
2 Nov 2025, 20:43 UTC
Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU
DJ
Read
2 Nov 2025, 20:42 UTC
Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU
DJ
Read
2 Nov 2025, 20:41 UTC
Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU
DJ
Read
2 Nov 2025, 20:40 UTC
Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU
DJ
Read
2 Nov 2025, 20:39 UTC
Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU
DJ
Read
2 Nov 2025, 20:37 UTC
Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU
DJ
Read
2 Nov 2025, 20:37 UTC
Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU
DJ
Read
2 Nov 2025, 20:37 UTC
Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU
DJ
Read
2 Nov 2025, 20:36 UTC
Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU
DJ
Read
2 Nov 2025, 20:35 UTC
Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU
DJ
Read
2 Nov 2025, 20:35 UTC
Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU
DJ
Read
2 Nov 2025, 20:35 UTC
Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU
DJ
Read
2 Nov 2025, 20:34 UTC
Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU
DJ
Read
2 Nov 2025, 20:33 UTC
Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU
DJ
Read
2 Nov 2025, 14:27 UTC
Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com
DJ
Read
2 Nov 2025, 14:25 UTC
Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 14 USD -15.97%
High 20 USD
Low 10 USD
Based on 3 Wall Street analysts offering 12 month price targets forLyell Immunopharma Inc - Dist in the last 3 months.
By TipRanks
Neutral
3 ratings
1
Buy
1
Hold
1
Sell
Based on 3 analysts giving stock ratings to Lyell Immunopharma Inc - Dist in the past 3 months.
By Trading Central
Short Term
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Weak Bearish Evidence
There is one bearish event.
Long Term
No Evidence
There are no events.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$